Use your antibodies-online credentials, if available.
Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
Alle Spezies anzeigen
Weitere Synonyme anzeigen
Wählen Sie die Spezies und Applikation aus
anti-Mouse (Murine) Kallikrein 10 Antikörper:
anti-Rat (Rattus) Kallikrein 10 Antikörper:
anti-Human Kallikrein 10 Antikörper:
Sie gelangen zu unserer vorgefilterten Suche.
Human Monoclonal Kallikrein 10 Primary Antibody für WB - ABIN968673
Goyal, Smith, Cowan, Wazer, Lee, Band: The role for NES1 serine protease as a novel tumor suppressor. in Cancer research 1998
Show all 3 Pubmed References
Human Polyclonal Kallikrein 10 Primary Antibody für IF (p), IHC (p) - ABIN741630
Wang, Schwab, Fan, Seagroves, Buolamwini: Chemoprevention Activity of Dipyridamole in the MMTV-PyMT Transgenic Mouse Model of Breast Cancer. in Cancer prevention research (Philadelphia, Pa.) 2013
Show all 2 Pubmed References
KLK10 was verified to be a potential therapeutic target for reversing trastuzumab resistance in breast cancer cells.
Pronounced correlations between KLK10/KLK11 (zeige KLK11 Antikörper) (rs = 0.647) and between KLK9 (zeige KLK9 Antikörper)/KLK15 (zeige KLK15 Antikörper) (rs = 0.716) mRNA, but not between other combinations, indicate coordinate expression of distinct pairs of peptidases
identification and molecular cloning of eight novel transcripts of the human KLK10 gene using 3' rapid amplification of cDNA ends (3' RACE) and next-generation sequencing (NGS), as well as their expression analysis in a wide panel of cell lines, originating from several distinct cancerous and normal tissues
Data suggest that mature KLK9 (kallikrein 9 (zeige KLK9 Antikörper)) is a glycosylated chymotrypsin-like enzyme with strong preference for tyrosine over phenylalanine at P1 cleavage position; substrate specificity of KLK9 (zeige KLK9 Antikörper) appears to extend to KLK10 and midkine (zeige MDK Antikörper); enzyme activity is enhanced by Mg2 (zeige MUC7 Antikörper)+ and Ca2 (zeige CA2 Antikörper)+, but is reversibly attenuated by Zn2+; KLK9 (zeige KLK9 Antikörper) is inhibited in vitro by many naturally occurring or synthetic protease inhibitors.
KLK10 potentially plays a crucial role in esophageal cancer cell growth.
KLK10 may function as a tumour suppressor by repressing proliferation, enhancing apoptosis and decreasing glucose metabolism in PC3 (zeige PCSK1 Antikörper) cells.
treated and untreated prolactin (zeige PRL Antikörper)-producing pituitary adenomas and carcinomas as well as TSH-producing pituitary adenomas and carcinomas were conclusively immunopositive for KLK10
Immunoexpression of KLK10 in the ACTH (zeige POMC Antikörper)-secreting tumors as well as in the Crooke cell tumors was significantly increased when compared with the nonfunctioning tumors and in the corticotrophs of non-tumorous pituitaries.
Data indicate that elevated expression of microRNA-375 in head and neck squamous cell carcinoma (HNSCC) cells significantly reduces kallikrein 6 (KLK6 (zeige KLK6 Antikörper)), kallikrein 10 (KLK10), and matrix metalloproteinase 9 (MMP9 (zeige MMP9 Antikörper)) messenger RNA expression.
is the first correlation of oral squamous cell carcinoma with KLK10 rs3745535G>T polymorphisms
Kallikreins are a subgroup of serine proteases having diverse physiological functions. Growing evidence suggests that many kallikreins are implicated in carcinogenesis and some have potential as novel cancer and other disease biomarkers. This gene is one of the fifteen kallikrein subfamily members located in a cluster on chromosome 19. Its encoded protein is secreted and may play a role in suppression of tumorigenesis in breast and prostate cancers. Alternate splicing of this gene results in multiple transcript variants encoding the same protein.
kallikrein-related peptidase 10
, kallikrein 10
, breast normal epithelial cell associated serine protease
, normal epithelial cell-specific 1
, protease serine-like 1
, protease, serine-like, 1